Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer

A 63‐year‐old woman was diagnosed with acute myelo‐monocytic leukaemia, associated with MLL gene rearrangement, 16 months after completion of oral capecitabine for metastatic colon cancer. Capecitabine, recommended for use in metastatic breast and colon cancer and more recently as adjuvant treatment...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of haematology Vol. 78; no. 6; pp. 543 - 544
Main Authors Shapiro, Susan, Hughes, George, Al‐Obaidi, Magda Jabbar, O’Reilly, Eamon, Ramesh, Subramanian, Smith, Jason, Ahmad, Riz, Dawson, Charlotte, Riddle, Pippa, Sekhar, Mallika
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.06.2007
Subjects
11q23
Acute Disease
acute myeloid leukaemia
Antimetabolites, Antineoplastic - adverse effects
Capecitabine
Colorectal Neoplasms - secondary
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
Fluorouracil - adverse effects
Fluorouracil - analogs & derivatives
Humans
Leukemia, Myeloid - chemically induced
Leukemia, Myeloid - pathology
MLL
secondary
Online AccessGet full text

Cover

More Information
Summary:A 63‐year‐old woman was diagnosed with acute myelo‐monocytic leukaemia, associated with MLL gene rearrangement, 16 months after completion of oral capecitabine for metastatic colon cancer. Capecitabine, recommended for use in metastatic breast and colon cancer and more recently as adjuvant treatment of colon cancer, has not previously been reported to be associated with secondary cancer.
ISSN:0902-4441
1600-0609
DOI:10.1111/j.1600-0609.2007.00864.x